These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 28445466)

  • 1. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.
    Merkle FT; Ghosh S; Kamitaki N; Mitchell J; Avior Y; Mello C; Kashin S; Mekhoubad S; Ilic D; Charlton M; Saphier G; Handsaker RE; Genovese G; Bar S; Benvenisty N; McCarroll SA; Eggan K
    Nature; 2017 May; 545(7653):229-233. PubMed ID: 28445466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous Single-Copy Loss of TP53 in Human Embryonic Stem Cells Markedly Increases Cell Proliferation and Survival.
    Amir H; Touboul T; Sabatini K; Chhabra D; Garitaonandia I; Loring JF; Morey R; Laurent LC
    Stem Cells; 2017 Apr; 35(4):872-885. PubMed ID: 27888558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational processes shape the landscape of TP53 mutations in human cancer.
    Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
    Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited importance of the dominant-negative effect of TP53 missense mutations.
    Stoczynska-Fidelus E; Szybka M; Piaskowski S; Bienkowski M; Hulas-Bigoszewska K; Banaszczyk M; Zawlik I; Jesionek-Kupnicka D; Kordek R; Liberski PP; Rieske P
    BMC Cancer; 2011 Jun; 11():243. PubMed ID: 21668955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs.
    Gerritsen M; Hilgendorf S; Yi G; Wierenga ATJ; Schuringa JJ; Martens JHA; Vellenga E
    Exp Hematol; 2022 Jun; 110():39-46. PubMed ID: 35315319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells.
    Itahana Y; Zhang J; Göke J; Vardy LA; Han R; Iwamoto K; Cukuroglu E; Robson P; Pouladi MA; Colman A; Itahana K
    Sci Rep; 2016 Jun; 6():28112. PubMed ID: 27346849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dominant-negative effect drives selection of
    Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL
    Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785
    [No Abstract]   [Full Text] [Related]  

  • 9. A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing.
    Zhou R; Xu A; Wang D; Zhu D; Mata H; Huo Z; Tu J; Liu M; Mohamed AMT; Jewell BE; Gingold J; Xia W; Rao PH; Hung MC; Zhao R; Lee DF
    Stem Cell Res; 2018 Mar; 27():131-135. PubMed ID: 29414603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing.
    Xu A; Zhou R; Tu J; Huo Z; Zhu D; Wang D; Gingold JA; Mata H; Rao PH; Liu M; Mohamed AMT; Kong CSL; Jewell BE; Xia W; Zhao R; Hung MC; Lee DF
    Stem Cell Res; 2018 May; 29():215-219. PubMed ID: 29730572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
    Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
    Liu Y; Bodmer WF
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of p53 in regulation of hematopoiesis in health and disease.
    Barajas S; Cai W; Liu Y
    Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of genetic and epigenetic instability in human embryonic stem cells associated with specific culture conditions.
    Garitaonandia I; Amir H; Boscolo FS; Wambua GK; Schultheisz HL; Sabatini K; Morey R; Waltz S; Wang YC; Tran H; Leonardo TR; Nazor K; Slavin I; Lynch C; Li Y; Coleman R; Gallego Romero I; Altun G; Reynolds D; Dalton S; Parast M; Loring JF; Laurent LC
    PLoS One; 2015; 10(2):e0118307. PubMed ID: 25714340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Pitfall of Pluripotent Stem Cells.
    Trounson A
    N Engl J Med; 2017 Aug; 377(5):490-491. PubMed ID: 28767348
    [No Abstract]   [Full Text] [Related]  

  • 17. De Novo Mutations Activating Germline TP53 in an Inherited Bone-Marrow-Failure Syndrome.
    Toki T; Yoshida K; Wang R; Nakamura S; Maekawa T; Goi K; Katoh MC; Mizuno S; Sugiyama F; Kanezaki R; Uechi T; Nakajima Y; Sato Y; Okuno Y; Sato-Otsubo A; Shiozawa Y; Kataoka K; Shiraishi Y; Sanada M; Chiba K; Tanaka H; Terui K; Sato T; Kamio T; Sakaguchi H; Ohga S; Kuramitsu M; Hamaguchi I; Ohara A; Kanno H; Miyano S; Kojima S; Ishiguro A; Sugita K; Kenmochi N; Takahashi S; Eto K; Ogawa S; Ito E
    Am J Hum Genet; 2018 Sep; 103(3):440-447. PubMed ID: 30146126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the Etiology of p53-mutated Cancer Cells.
    Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
    J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.